HAWTHORNE, N.Y., Nov. 8, 2006 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,”) (Nasdaq:TARO) reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (ANDA”) for Meloxicam Tablets, 7.5 mg and 15 mg (“meloxicam tablets”).
